ProCE Banner Activity

JAK-POT: Real-World Risk of Treatment Discontinuation Across 17 International Registers of Patients With Rheumatoid Arthritis

Slideset Download
Conference Coverage
Numerically lower probability of discontinuation with JAK inhibitors vs TNF inhibitors in adjusted analysis of 25,521 patients with rheumatoid arthritis.

Released: July 01, 2020

Expiration: June 30, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AbbVie Inc.

Gilead Sciences, Inc.